Skip to main content
PMC home page
Journal of the Royal Society of Medicine logoLink to Journal of the Royal Society of Medicine
. 1983 Feb;76(2):144–148. doi: 10.1177/014107688307600212

Chemotherapy and the adult gonad: a review.

J Waxman
PMCID: PMC1438671  PMID: 6338232

Full text

PDF
144

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bergquist C., Nillius S. J., Wide L. Inhibition of ovulation in women by intranasal treatment with a luteinizing hormone-releasing hormone agonist. Contraception. 1979 May;19(5):497–506. doi: 10.1016/0010-7824(79)90064-7. [DOI] [PubMed] [Google Scholar]
  2. Bonadonna G., Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981 Jan 1;304(1):10–15. doi: 10.1056/NEJM198101013040103. [DOI] [PubMed] [Google Scholar]
  3. Brook C. G., Dombey S. Induction of puberty: long-term treatment with high-dose LHRH. Clin Endocrinol (Oxf) 1979 Jul;11(1):81–87. doi: 10.1111/j.1365-2265.1979.tb03049.x. [DOI] [PubMed] [Google Scholar]
  4. Bulbrook R. D., Moore J. W., Clark G. M., Wang D. Y., Tong D., Hayward J. L. Plasma oestradiol and progesterone levels in women with varying degrees of risk of breast cancer. Eur J Cancer. 1978 Dec;14(12):1369–1375. doi: 10.1016/0014-2964(78)90120-2. [DOI] [PubMed] [Google Scholar]
  5. Chapman R. M., Sutcliffe S. B., Malpas J. S. Cytotoxic-induced ovarian failure in women with Hodgkin's disease. I. Hormone function. JAMA. 1979 Oct 26;242(17):1877–1881. [PubMed] [Google Scholar]
  6. Chapman R. M., Sutcliffe S. B., Malpas J. S. Male gonadal dysfunction in Hodgkin's disease. A prospective study. JAMA. 1981 Apr 3;245(13):1323–1328. [PubMed] [Google Scholar]
  7. Chapman R. M., Sutcliffe S. B., Rees L. H., Edwards C. R., Malpas J. S. Cyclical combination chemotherapy and gonadal function. Retrospective study in males. Lancet. 1979 Feb 10;1(8111):285–289. doi: 10.1016/s0140-6736(79)90701-3. [DOI] [PubMed] [Google Scholar]
  8. Cheviakoff S., Calamera J. C., Morgenfeld M., Mancini R. E. Recovery of spermatogenesis in patients with lymphoma after treatment with chlorambucil. J Reprod Fertil. 1973 Apr;33(1):155–157. doi: 10.1530/jrf.0.0330155. [DOI] [PubMed] [Google Scholar]
  9. Etteldorf J. N., West C. D., Pitcock J. A., Williams D. L. Gonadal function, testicular histology, and meiosis following cyclophosphamide therapy in patients with nephrotic syndrome. J Pediatr. 1976 Feb;88(2):206–212. doi: 10.1016/s0022-3476(76)80983-3. [DOI] [PubMed] [Google Scholar]
  10. Fairley K. F., Barrie J. U., Johnson W. Sterility and testicular atrophy related to cyclophosphamide therapy. Lancet. 1972 Mar 11;1(7750):568–569. doi: 10.1016/s0140-6736(72)90358-3. [DOI] [PubMed] [Google Scholar]
  11. Fisher B., Sherman B., Rockette H., Redmond C., Margolese R., Fisher E. R. 1-phenylalanine mustard (L-PAM) in the management of premenopausal patients with primary breast cancer: lack of association of disease-free survival with depression of ovarian function. National Surgical Adjuvant Project for Breast and Bowel Cancers. Cancer. 1979 Sep;44(3):847–857. doi: 10.1002/1097-0142(197909)44:3<847::aid-cncr2820440309>3.0.co;2-3. [DOI] [PubMed] [Google Scholar]
  12. Fraser H. M., Laird N. C., Blakeley D. M. Decreased pituitary responsiveness and inhibition of the luteinizing hormone surge and ovulation in the stumptailed monkey (Macaca arctoides) by chronic treatment with an agonist of luteinizing hormone-releasing hormone. Endocrinology. 1980 Feb;106(2):452–457. doi: 10.1210/endo-106-2-452. [DOI] [PubMed] [Google Scholar]
  13. GRATTAROLA R. THE PREMENSTRUAL ENDOMETRIAL PATTERN OF WOMEN WITH BREAST CANCER. A STUDY OF PROGESTATIONAL ACTIVITY. Cancer. 1964 Sep;17:1119–1122. doi: 10.1002/1097-0142(196409)17:9<1119::aid-cncr2820170904>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  14. Glode L. M., Robinson J., Gould S. F. Protection from cyclophosphamide-induced testicular damage with an analogue of gonadotropin-releasing hormone. Lancet. 1981 May 23;1(8230):1132–1134. doi: 10.1016/s0140-6736(81)92301-1. [DOI] [PubMed] [Google Scholar]
  15. Himelstein-Braw R., Peters H., Faber M. Morphological study of the ovaries of leukaemic children. Br J Cancer. 1978 Jul;38(1):82–87. doi: 10.1038/bjc.1978.166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Jacobs C., Portlock C. S., Rosenberg S. A. Prednisone in MOPP chemotherapy for Hodgkin's disease. Br Med J. 1976 Dec 18;2(6050):1469–1471. doi: 10.1136/bmj.2.6050.1469. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Koyama H., Wada T., Nishizawa Y., Iwanaga T., Aoki Y. Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer. 1977 Apr;39(4):1403–1409. doi: 10.1002/1097-0142(197704)39:4<1403::aid-cncr2820390408>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  18. LANDING B. H., GOLDIN A., NOE H. A. Testicular lesions in mice following parenteral administration of nitrogen mustards. Cancer. 1949 Nov;2(6):1075-82, illust. doi: 10.1002/1097-0142(194911)2:6<1075::aid-cncr2820020612>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  19. LOUIS J., LIMARZI L. R., BEST W. R. Treatment of chronic granulocytic leukemia with myleran. AMA Arch Intern Med. 1956 Mar;97(3):299–308. doi: 10.1001/archinte.1956.00250210045003. [DOI] [PubMed] [Google Scholar]
  20. Linde R., Doelle G. C., Alexander N., Kirchner F., Vale W., Rivier J., Rabin D. Reversible inhibition of testicular steroidogenesis and spermatogenesis by a potent gonadotropin-releasing hormone agonist in normal men: an approach toward the development of a male contraceptive. N Engl J Med. 1981 Sep 17;305(12):663–667. doi: 10.1056/NEJM198109173051203. [DOI] [PubMed] [Google Scholar]
  21. Mancini R. E., Lavieri J. C., Muller F., Andrada J. A., Saraceni D. J. Effect of prednisolone upon normal and pathologic human spermatogenesis. Fertil Steril. 1966 Jul-Aug;17(4):500–513. doi: 10.1016/s0015-0282(16)36008-3. [DOI] [PubMed] [Google Scholar]
  22. Nillius S. J., Bergquist C., Wide L. Inhibition of ovulation in women by chronic treatment with a stimulatory LRH analogue--a new approach to birth control? Contraception. 1978 Jun;17(6):537–545. [PubMed] [Google Scholar]
  23. Richter P., Calamera J. C., Morgenfeld M. C., Kierszenbaum A. L., Lavieri J. C., Mancini R. E. Effect of chlorambucil on spermatogenesis in the human with malignant lymphoma. Cancer. 1970 May;25(5):1026–1030. doi: 10.1002/1097-0142(197005)25:5<1026::aid-cncr2820250506>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  24. Roeser H. P., Stocks A. E., Smith A. J. Testicular damage due to cytotoxic drugs and recovery after cessation of therapy. Aust N Z J Med. 1978 Jun;8(3):250–254. doi: 10.1111/j.1445-5994.1978.tb04518.x. [DOI] [PubMed] [Google Scholar]
  25. Rose D. P., Davis T. E. Effects of adjuvant chemohormonal therapy on the ovarian and adrenal function of breast cancer patients. Cancer Res. 1980 Nov;40(11):4043–4047. [PubMed] [Google Scholar]
  26. Samaan N. A., deAsis D. N., Jr, Buzdar A. U., Blumenschein G. R. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978 Jun;41(6):2084–2087. doi: 10.1002/1097-0142(197806)41:6<2084::aid-cncr2820410603>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  27. Sanger W. G., Armitage J. O., Schmidt M. A. Feasibility of semen cryopreservation in patients with malignant disease. JAMA. 1980 Aug 22;244(8):789–790. [PubMed] [Google Scholar]
  28. Schulz K. D., Schmidt-Rhode P., Weymar P., Künzig H. J., Geiger W. The effect of combination chemotherapy on ovarian, hypothalamic and pituitary function in patients with breast cancer. Arch Gynecol. 1979;227(4):293–301. doi: 10.1007/BF02109918. [DOI] [PubMed] [Google Scholar]
  29. Shalet S. M., Hann I. M., Lendon M., Morris Jones P. H., Beardwell C. G. Testicular function after combination chemotherapy in childhood for acute lymphoblastic leukaemia. Arch Dis Child. 1981 Apr;56(4):275–278. doi: 10.1136/adc.56.4.275. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Sherins R. J., DeVita V. T., Jr Effect of drug treatment for lymphoma on male reproductive capacity. Studies of men in remission after therapy. Ann Intern Med. 1973 Aug;79(2):216–220. doi: 10.7326/0003-4819-79-2-216. [DOI] [PubMed] [Google Scholar]
  31. Sieber S. M., Correa P., Dalgard D. W., Adamson R. H. Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res. 1978 Jul;38(7):2125–2134. [PubMed] [Google Scholar]
  32. Siris E. S., Leventhal B. G., Vaitukaitis J. L. Effects of childhood leukemia and chemotherapy on puberty and reproductive function in girls. N Engl J Med. 1976 May 20;294(21):1143–1146. doi: 10.1056/NEJM197605202942102. [DOI] [PubMed] [Google Scholar]
  33. Sobrinho L. G., Levine R. A., DeConti R. C. Amenorrhea in patients with Hodgkin's disease treated with antineoplastic agents. Am J Obstet Gynecol. 1971 Jan 1;109(1):135–139. doi: 10.1016/0002-9378(71)90848-9. [DOI] [PubMed] [Google Scholar]
  34. Tcholakian R. K., de la Cruz A., Chowdhury M., Steinberger A., Coy D. H., Schally A. V. Unusual anti-reproductive properties of the analog [d-Leu6,des-Gly-NH2(10)]-luteinizing hormone-releasing hormone ethylamide in male rats. Fertil Steril. 1978 Nov;30(5):600–603. [PubMed] [Google Scholar]
  35. Vermeulen A., Suy E., Rubens R. Effect of prolactin on plasma DHEA (s) levels. J Clin Endocrinol Metab. 1977 Jun;44(6):1222–1225. doi: 10.1210/jcem-44-6-1222. [DOI] [PubMed] [Google Scholar]
  36. Warne G. L., Fairley K. F., Hobbs J. B., Martin F. I. Cyclophosphamide-induced ovarian failure. N Engl J Med. 1973 Nov 29;289(22):1159–1162. doi: 10.1056/NEJM197311292892202. [DOI] [PubMed] [Google Scholar]
  37. Waxman J. H., Terry Y. A., Wrigley P. F., Malpas J. S., Rees L. H., Besser G. M., Lister T. A. Gonadal function in Hodgkin's disease: long-term follow-up of chemotherapy. Br Med J (Clin Res Ed) 1982 Dec 4;285(6355):1612–1613. doi: 10.1136/bmj.285.6355.1612. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of the Royal Society of Medicine are provided here courtesy of Royal Society of Medicine Press

RESOURCES